Axovant Sciences (AXON) Sinks 17% on Eli Lilly Sola Failure

November 23, 2016 7:50 AM EST
Get Alerts AXON Hot Sheet
Trade AXON Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Axovant Sciences (NYSE: AXON) is down 17% in pre-open trade after Eli Lilly & Co. (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Trader Talk

Related Entities

Pre Market Movers

Add Your Comment